Patents by Inventor Steffi LUNDVALL

Steffi LUNDVALL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY
    Publication number: 20230263155
    Abstract: The invention relates to the use of compounds of formula (I), stereoisomers, and physiologically tolerable salts thereof, to enhance the motility of sperm obtained from a non-human mammal: wherein in formula I: X is —NR?— (in which R? is H or C1-3 alkyl, e,g, —CH3), —O—, —S— or —CH2—; Y is —S—, —O—, —NR?— (in which R? is H or C1-3 alkyl, e.g.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 24, 2023
    Inventors: Ken Roger ROSENDAL, Tuva Holt HERENG, Steffi LUNDVALL, Espen Marcelius GJEMS, Håvard Hildeng HAUGE, Bjørn Steen SKÅLHEGG
  • LDHA activity inhibitors
    Patent number: 11142520
    Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: October 12, 2021
    Assignee: ARCTIC PHARMA AS
    Inventors: Jo Klaveness, Bora Sieng, Steffi Lundvall, Claudia Alejandra Bøen, Kathrin Hnida
  • PIPERIDINE-DIONE DERIVATIVES FOR USE AS CONTRACEPTIVES
    Publication number: 20200163950
    Abstract: The invention relates to a method of reducing sperm motility or of contraception in a subject, said method comprising the step of administering to said subject an effective amount of a compound of formula (I), a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein.
    Type: Application
    Filed: May 16, 2018
    Publication date: May 28, 2020
    Inventors: Bora SIENG, Steffi LUNDVALL, Claudia Alejandra BØEN, Kathrin HNIDA, Jo KLAVENESS
  • LDHA ACTIVITY INHIBITORS
    Publication number: 20200165233
    Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Application
    Filed: May 16, 2018
    Publication date: May 28, 2020
    Inventors: Jo KLAVENESS, Bora SIENG, Steffi LUNDVALL, Claudia Alejandra BØEN, Kathrin HNIDA
  • LDHA ACTIVITY INHIBITORS
    Publication number: 20200102293
    Abstract: The invention provides compounds of formula (I), stereoisomers and pharmaceutically acceptable salts thereof: (I) wherein A1 to A4, R1 and RP are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Application
    Filed: May 16, 2018
    Publication date: April 2, 2020
    Inventors: Jo KLAVENESS, Bora Sieng, Steffi LUNDVALL, Claudia Alejandra BØEN, Kathrin HNIDA